Sep 2026· Oncology and Therapy· 0 citations· 87 references
Medicine
TL;DR
A retrospective secondary analysis of comprehensive genomic and immune profiling data from 1737 patients with colorectal cancer tested showed that tumours arising in patients with EOCRC had lower tumour mutational burden than tumours diagnosed as LOCRC, whereas other immune-related biomarkers did not remain significantly different after correction for multiple testing.
Abstract
Early‑onset colorectal cancer (EOCRC), defined as colorectal cancer (CRC) diagnosed before 50 years of age, is increasing globally. Colorectal cancer is currently the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide, with GLOBOCAN 2024 estimating approximately 2.04 million new cases and 917,895 deaths in 2024. Recent studies indicate a sustained rise in EOCRC incidence across multiple regions and birth cohorts, with the greatest increases observed among younger adults. Although hereditary cancer syndromes account for 20-25% of EOCRC cases, most occur in the absence of known genetic predispositions or established risk factors. Emerging evidence implicates the gut microbiome as a potential contributor to EOCRC, with distinct microbial signatures differentiating it from late‑onset colorectal cancer (LOCRC) diagnosed after 50 years of age. This review synthesizes current evidence on clinical, molecular, and diagnostic features distinguishing EOCRC from LOCRC, including differences in anatomical distribution, histopathology, genomic and epigenetic alterations, microbiome composition, and immune landscape, and discusses their implications for personalised screening and therapeutic strategies. We performed a retrospective secondary analysis of comprehensive genomic and immune profiling data from 1737 patients with colorectal cancer tested between June 2021 and June 2023. The analysis showed that tumours arising in patients with EOCRC had lower tumour mutational burden than tumours diagnosed as LOCRC, whereas other immune-related biomarkers, including tumour immunogenicity score, did not remain significantly different after correction for multiple testing. Despite these emerging biological differences, current screening strategies remain largely dependent on an age threshold of 50 years, and EOCRC is not addressed by age‑specific treatment approaches. We therefore review the translational potential of emerging biomarkers, including microbial signatures and liquid biopsy approaches, and propose a framework for integrating molecular profiling into clinical practice. Finally, we highlight the unmet need for coordinated efforts to improve screening in younger populations, address fertility preservation considerations, and ensure adequate psychosocial support for patients with EOCRC.
Although overall colorectal cancer (CRC) incidence and mortality have declined with widespread screening, early-onset CRC (EOCRC), defined as diagnosis before age 50, continues to rise. EOCRC partially differs from late-onset CRC (LOCRC) in clinical presentation, molecular features, polyp characteristics, and patterns...
Vanessa Lu, Fiona Xu, G. Graziosi et al.· Gastroenterology Insights· 0 citations
Objective: The increasing incidence of early-onset colorectal cancer (EO-CRC) has raised the question of whether these tumors exhibit different molecular characteristics from late-onset colorectal cancer (LO-CRC). We aimed to compare the somatic genomic profiles of EO-CRC and LO-CRC.
Materials and Methods: Clinical and...
Bengi Öztürk, H. A. Yaşar, Onur Keskin et al.· Acta medica· 0 citations
This review critically synthesizes recent evidence on EOCRC epidemiology, risk architecture, life-course carcinogenesis, molecular and microbiome-associated mechanisms, diagnostic delay, screening limitations, treatment considerations, and survivorship needs, with the aim of reframing EOCRC as an age-attuned clinical a...
Magda Grześkiewicz-Szostak, K. Gęca, M. Skórzewska· Current Oncology Reports· 0 citations
Findings indicate that youth does not confer prognostic advantage and support the need for targeted prevention, earlier recognition and tailored research efforts focused on gastric cancer in younger populations.
Unaiza Waheed, Abigail Burn, A. Ribbits et al.· Diseases of the esophagus· 0 citations
Differences in mutations of key genes including a lower prevalence of APC mutations and increased SMAD4 mutations in younger individuals provides further supporting evidence that early-onset CRC may represent a distinct biological subtype of CRC.
L. Liu, A. Rose, A. Samaddar et al.· ESMO gastrointestinal oncolo...· 0 citations
Evidence shows that EOCRC is disproportionately distal or rectal and is often diagnosed at stage III or IV, and earlier symptom recognition, risk-based assessment, germline testing, and timely colonoscopy are therefore central to reducing preventable late diagnoses.
Eduarda de Oliveira Mainardi, Fabrício da Cunha Moraes, Manuella Hassan Salman· International Health Science...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.